What's New And What's Next In CAR-T After ASH

 
• By Mandy Jackson

Incremental updates at the recent ASH meeting shed light on which products may follow Novartis' Kymriah and Gilead/Kite's Yescarta into the commercial market. Will it be Celgene and Bluebird or Celgene and Juno? Where do Pfizer, Servier and Cellectis stand with their off-the-shelf options?

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment

More from Immuno-oncology

More from Anticancer